Fairvalue-Calculator Fairvalue-Calculator
EN DE

Universal Ibogaine Inc (IBOGF) Fair Value & Analysis

Healthcare · US · Market cap $7.3M

Price$0.0272
Fair Value$0.0100
Upside-63.2%
Quality92/100
Evidence: Low Range $0.0100 – $0.0100

Fair value as of: Jun 24, 2026

Analysis

Universal Ibogaine Inc (IBOGF) currently trades at $0.0272, while our model-based Fair Value estimate is $0.0100 — implying the stock looks roughly 63.2% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is Universal Ibogaine Inc (IBOGF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.0100 versus a price of $0.0272 — about −63% (overvalued). Model-based estimate, not financial advice.
What is the fair value of IBOGF?
Our 21-model fair value for Universal Ibogaine Inc is $0.0100 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.0272.
What is the quality score of IBOGF?
Universal Ibogaine Inc has a Quality Score of 92/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.